SynthesisVeterinary research communications2026
Cardiovascular biomarkers in feline hypertrophic cardiomyopathy phenotype: evidence from the last decade.
Synthesis in Veterinary research communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The hypertrophic cardiomyopathy (HCM) phenotype is the most common feline cardiovascular condition, characterized by myocardial hypertrophy and variable hemodynamic changes, with diagnosis primarily based on echocardiography. However, cardiovascular biomarkers have gained increasing importance in the diagnostic assessment of the HCM phenotype. This systematic review aimed to evaluate the utility of cardiovascular-related biomarkers in the diagnosis of HCM in cats, in order to determine their clinical potential and utility. A systematic search was conducted in PubMed, Scopus, and Web of Science over a last decade (January 2015 - June 2025). Study selection was performed by a single reviewer, and risk-of-bias assessment by two reviewers using the Joanna Briggs Institute (JBI) tools. Studies providing relevant data on the use of cardiovascular biomarkers in cats with the HCM phenotype were included. Data regarding study design, population characteristics, biomarker type, and clinical associations were extracted and analyzed. Out of 220 initially screened studies, 63 met the inclusion criteria and the majority were considered of high methodological quality with low risk of bias. The most frequently reported biomarkers were N-terminal pro-B-type natriuretic peptide (NT-proBNP) and cardiac troponin I (cTnI), both commonly associated with clinical status, echocardiographic findings, and prognostic risk. Other emerging biomarkers, including molecular and genetic markers related to myocardial remodeling and fibrosis, demonstrated potential clinical utility, although further investigation is still required. Overall, despite robust scientific evidence, biomarkers play an adjunctive role in the evaluation of the feline HCM phenotype. Echocardiography remains the gold standard for definitive diagnosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.